Compare Ascendis Pharma A/S (ASND) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Nebius Group NV — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Nebius Group NV trades at $212.33 (market cap $55.77B). The key difference: Nebius Group NV is far larger — about 3.1× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| ASND | NBIS | |
|---|---|---|
Market Cap | $17.74B | $55.77B |
Sector | Health | Technology |
52-Week High | $277.18 | $286.69 |
52-Week Low | $163.32 | $44.30 |
Enterprise Value | $18.11B | $55.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NBIS trades at $219.65, up 1.6% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $529.80 million in 2025 with a net income of $82.50 million, and analyst consensus is strongly bullish with an average price target of $248.00. Recent news highlights aggressive AI infrastructure expansion and partnerships, though volatility persists amid sector competition fears.
Outlook remains positive given strong analyst buy ratings and projected revenue growth to $878 million in 2026, but high valuation multiples and competitive threats from tech giants like Meta pose significant risks. Cash flow trends show heavy investing activity funded by financing, supporting growth but elevating leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
